FDA advisers divided on Sanofi’s oral type 1 diabetes drugThe future of Sanofi and Lexicon’s oral diabetes drug Zynquista hangs in the balance after an FDA advisory Share XFDA advisers divided on Sanofi’s oral type 1 diabetes drughttps://pharmaphorum.com/news/fda-divided-on-sanofis-oral-type-1-diabetes-drug/
Novartis and Oxford University begin R&D tie-upNovartis and Oxford University have begun a partnership that will attempt to use artificial intelligence to predict how Share XNovartis and Oxford University begin R&D tie-uphttps://pharmaphorum.com/news/novartis-and-oxford-university-begin-rd-tie-up/
J&J partners with Apple for ECG monitoring projectApple has a new big pharma partner to help put its new Apple Watch with built-in electrocardiogram (ECG) Share XJ&J partners with Apple for ECG monitoring projecthttps://pharmaphorum.com/news/jj-partners-with-apple-for-ecg-monitoring-project/
Communiqué Awards 2019 opens for healthcare comms entriesThe Communiqué Awards 2019 have launched, seeking entries in European, international and local healthcare communications. The UK-based med Share XCommuniqué Awards 2019 opens for healthcare comms entrieshttps://pharmaphorum.com/news/communique-awards-2019-launch/
Telehealth firm secures more cash to expand in China, Japan and USTelehealth firm Tyto Care has secured additional funding to help with the launch of its technology allowing for Share XTelehealth firm secures more cash to expand in China, Japan and UShttps://pharmaphorum.com/news/telehealth-firm-secures-more-cash-to-expand-in-china-japan-and-us/
FDA advisers back Amgen/UCB’s osteoporosis drug EvenityAmgen’s bone-building drug Evenity looks on course for US approval in certain women with osteoporosis after a panel Share XFDA advisers back Amgen/UCB’s osteoporosis drug Evenityhttps://pharmaphorum.com/news/fda-advisers-back-amgen-ucbs-osteoporosis-drug-evenity/
Lilly’s Verzenios approved by NICENICE has published draft guidance that now recommends Eli Lilly’s breast cancer drug Verzenios for use on the Share XLilly’s Verzenios approved by NICEhttps://pharmaphorum.com/news/lillys-verzenios-approved-nice/
UK researchers investigate alternatives to long-term opioid useA UK university has been awarded £2.4 million to research overprescribing of opioids, and how to improve treatment Share XUK researchers investigate alternatives to long-term opioid usehttps://pharmaphorum.com/news/uk-researchers-investigate-alternatives-to-long-term-opioid-use/
United Neuroscience inches closer to Alzheimer’s vaccine prizeA vaccine for Alzheimer’s disease developed by United Neuroscience has cleared a phase IIa trial, and seems to Share XUnited Neuroscience inches closer to Alzheimer’s vaccine prizehttps://pharmaphorum.com/news/united-neuroscience-alzheimers-vaccine/
Page & Page appoints Clare Bates as editorial directorUK creative and communications agency Page & Page has appointed Clare Bates as editorial director. She brings to Share XPage & Page appoints Clare Bates as editorial directorhttps://pharmaphorum.com/sales-marketing/page-and-page-clare-bates/
Sandoz selects finalists in digital tech healthcare access competitionSandoz has selected three finalists in a competition to use digital technology to increase access to medicines in Share XSandoz selects finalists in digital tech healthcare access competitionhttps://pharmaphorum.com/news/sandoz-selects-finalists-in-digital-tech-healthcare-access-competition/
Ex-Roche, Novartis, AstraZeneca leaders appointed to biotech rolesThree more big pharma R&D names have made the jump to biotech as Voyager Therapeutics, ImmunSYS and Immunocore Share XEx-Roche, Novartis, AstraZeneca leaders appointed to biotech roleshttps://pharmaphorum.com/news/ex-roche-novartis-astrazeneca-leaders-appointed-to-biotech-roles/
Pharma calls for ‘no deal’ preparation after Brexit deal rejectedPharma has called for politicians to take action to ensure patient safety in the event of a ‘no Share XPharma calls for ‘no deal’ preparation after Brexit deal rejectedhttps://pharmaphorum.com/news/pharma-calls-for-no-deal-preparation-after-brexit-deal-rejected/
FDA delays review of peanut allergy drug amid Trump shutdownOne of the first pharma victims of the current partial shutdown of the US government has emerged after Share XFDA delays review of peanut allergy drug amid Trump shutdownhttps://pharmaphorum.com/news/fda-delays-review-of-peanut-allergy-drug-amid-trump-shutdown/
BMS gets new OK for Opdivo/Yervoy in kidney cancerBristol-Myers Squibb has claimed a new approval for its immuno-oncology combination of Opdivo and Yervoy, getting a green Share XBMS gets new OK for Opdivo/Yervoy in kidney cancerhttps://pharmaphorum.com/news/bms-gets-new-ok-for-opdivo-yervoy-in-kidney-cancer/
Lucid Group appoints Rob Apollo to its senior leadership teamLucid Group has expanded its senior leadership team with the appointment of Rob Apollo as director of corporate Share XLucid Group appoints Rob Apollo to its senior leadership teamhttps://pharmaphorum.com/news/lucid-group-rob-apollo/
Digital health innovators get boost in Yorkshire and HumberA new NHS-backed scheme is to turbo-charge digital health innovation across England’s Yorkshire and Humber and region. The Share XDigital health innovators get boost in Yorkshire and Humberhttps://pharmaphorum.com/news/digital-health-innovators-get-boost-in-yorkshire-and-humber/
Exelixis’ Cabometyx approved in second-line liver cancer in USExelixis’ cancer drug Cabometyx has been approved in a new liver cancer use in the US, providing a Share XExelixis’ Cabometyx approved in second-line liver cancer in UShttps://pharmaphorum.com/news/exelixis-cabometyx-approved-in-second-line-liver-cancer-in-us/
Pharmaceutical Microbiology UK CONFEX takes place in less than a week! Share XPharmaceutical Microbiology UK CONFEX takes place in less than a week!https://pharmaphorum.com/partner-content/pharmaceutical-microbiology-uk-confex-takes-place-in-less-than-a-week/
Tom Parke to lead a workshop on the new FDA draft guidance Share XTom Parke to lead a workshop on the new FDA draft guidancehttps://pharmaphorum.com/partner-content/tom-parke-to-lead-a-workshop-on-the-new-fda-draft-guidance/
Join Pharmaceutical Social Media Experts in Just 1 Week! Share XJoin Pharmaceutical Social Media Experts in Just 1 Week!https://pharmaphorum.com/partner-content/join-pharmaceutical-social-media-experts-in-just-1-week-2/
Three-dimensional cell cultures as predictive tools in early drug discovery Share XThree-dimensional cell cultures as predictive tools in early drug discoveryhttps://pharmaphorum.com/partner-content/three-dimensional-cell-cultures-as-predictive-tools-in-early-drug-discovery/
pharmaphorum welcomes George Underwood to its editorial helm Share Xpharmaphorum welcomes George Underwood to its editorial helmhttps://pharmaphorum.com/news/pharmaphorum-welcomes-george-underwood-to-its-editorial-helm/
STEM Healthcare appoints Jason McKenna as CEO Share XSTEM Healthcare appoints Jason McKenna as CEOhttps://pharmaphorum.com/partner-content/stem-healthcare-appoints-jason-mckenna-as-ceo/
